Nascent Biotech, Inc. (NBIO)
OTCMKTS · Delayed Price · Currency is USD
0.0023
0.00 (0.00%)
Nov 5, 2025, 4:00 PM EST
Nascent Biotech Statistics
Total Valuation
Nascent Biotech has a market cap or net worth of 397,538. The enterprise value is 409,148.
| Market Cap | 397,538 |
| Enterprise Value | 409,148 |
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nascent Biotech has 172.84 million shares outstanding.
| Current Share Class | 172.84M |
| Shares Outstanding | 172.84M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.62% |
| Owned by Insiders (%) | 48.02% |
| Owned by Institutions (%) | n/a |
| Float | 89.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -0.77 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.21 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.31
| Current Ratio | 0.31 |
| Quick Ratio | 0.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -854.34% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 406.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.82% in the last 52 weeks. The beta is 1.62, so Nascent Biotech's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -95.82% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 41.69 |
| Average Volume (20 Days) | 36,878 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | -297,626 |
| Operating Income | -2.09M |
| Pretax Income | -1.92M |
| Net Income | -1.92M |
| EBITDA | n/a |
| EBIT | -2.09M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 47,391 in cash and 59,000 in debt, giving a net cash position of -11,609 or -0.00 per share.
| Cash & Cash Equivalents | 47,391 |
| Total Debt | 59,000 |
| Net Cash | -11,609 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -514,540 |
| Book Value Per Share | -0.00 |
| Working Capital | -514,540 |
Cash Flow
| Operating Cash Flow | -1.35M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nascent Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.53% |
| Shareholder Yield | -30.53% |
| Earnings Yield | -484.19% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |